Elanco Animal Health Inc. is investing $130 million to expand and renovate its manufacturing facility in Elwood, Kansas, Gov. Laura Kelly announced. The expansion in Doniphan County is expected to create approximately 70 new jobs over the next two years.
Elanco’s Elwood site currently manufactures and ships its Canine Parvovirus Monoclonal Antibody and will be the flagship location for Elanco’s future monoclonal antibody manufacturing. This product is the first and only U.S. Department of Agriculture conditionally approved targeted treatment for parvovirus, which affects an estimated 330,000 dogs annually in the United States.
The expansion will add the needed capacity to support Elanco’s growth in monoclonal antibody innovation.
